Evogliptin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Evogliptin
Evogliptin.svg
Clinical data
Trade names Suganon
Synonyms DA-1229
Routes of
administration
By mouth
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C19H26F3N3O3
Molar mass 401.43 g·mol−1
3D model (JSmol)

Evogliptin (INN; trade name Suganon) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea.[2]

References[edit]

  1. ^ McCormack PL. (2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–2049. doi:10.1007/s40265-015-0496-5. PMID 26541763.
  2. ^ "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015.